Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Lp(a)-Lowering siRNA Market: Olpasiran and Lepodisiran Outcomes Trial Demand, Ultra-Long-Duration Dosing Growth, and GalNAc-Conjugated Hepatocyte Targeting Adoption to Drive Exceptional Market Expansion Through 2035

The global Lp(a)-Lowering siRNA Market is projected to expand at an exceptional CAGR of 34.0% through 2035, driven by sustained demand generated by pivotal cardiovascular outcomes trials evaluating olpasiran and lepodisiran, growing adoption of ultra-long-duration dosing technology, and continued reliance on GalNAc-conjugated hepatocyte targeting. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises three lead clinical-stage candidates—olpasiran, lepodisiran, and zerlasiran—with a 2026 network meta-analysis identifying siRNA as the most potent Lp(a)-lowering modality class evaluated.

The market’s exceptional 34.0% CAGR reflects the clinical differentiation of siRNA technology as the most potent Lp(a)-lowering modality among competing approaches, generating structured anticipated demand from cardiology treatment centers well above discretionary specialty pharmaceutical growth rates. Reported reduction magnitudes of approximately 92% for olpasiran and approximately 94% for lepodisiran in the cited evidence base continue to reinforce siRNA’s leading efficacy position, while lepodisiran’s demonstrated sustained Lp(a) reduction for more than 12 months following a single dose represents an exceptional durability profile within the broader cardiovascular therapeutics landscape. Coverage extending across multiple dosing intervals, patient risk profiles, and clinical endpoints underscores the breadth of clinical infrastructure now supporting this category ahead of its anticipated first approvals.

Executive Snapshot

How does olpasiran and lepodisiran outcomes trial demand drive the Lp(a)-lowering siRNA market?
Cardiology treatment centers continue to enroll patients across the pivotal OCEAN(a)-Outcomes trial evaluating olpasiran and the ACCLAIM-Lp(a) trial evaluating lepodisiran, establishing these two lead siRNA candidates as the primary drivers of near-term market development. As these outcomes trials progress toward completion, procurement associated with siRNA-based Lp(a) reduction is expected to remain the dominant modality category through the forecast period.

What role does ultra-long-duration dosing growth play in market expansion?
Biopharmaceutical developers continue to advance siRNA candidates capable of sustained Lp(a) reduction following single-dose administration, with lepodisiran demonstrating durable effect for more than 12 months in reported clinical evidence, sustaining structured demand from developers pursuing maximally infrequent dosing schedules relative to other cardiovascular therapeutic classes.

How does GalNAc-conjugated hepatocyte targeting adoption sustain market growth?
Biopharmaceutical developers continue to rely on GalNAc-conjugated siRNA architecture across all three lead clinical programs to achieve targeted hepatic delivery, sustaining structured demand above conventional non-conjugated siRNA delivery baselines. Continued technology investment in this targeted delivery approach is generating demand from developers pursuing improved liver-specific Lp(a) biosynthesis suppression.

What is driving demand for siRNA-based Lp(a) reduction in primary cardiovascular prevention applications?
Developers pursuing olpasiran’s expanding development program into primary cardiovascular prevention continue to extend siRNA-based Lp(a) reduction beyond secondary prevention in established cardiovascular disease patients, generating incremental demand among clinical-stage biopharmaceutical developers pursuing broader addressable patient populations.

How does zerlasiran’s completed Phase II data sustain the market?
Biopharmaceutical developers and potential commercialization partners continue to evaluate zerlasiran following completed Phase II development, with continued Phase III outcomes development contingent on partnering activity, sustaining structured demand from developers pursuing durable extended-interval siRNA-based Lp(a) reduction.

Which Lp(a)-lowering siRNA market segments are growing fastest?
The fastest-growing segments include ultra-long-duration dosing formats extending beyond quarterly administration, primary cardiovascular prevention applications, GalNAc-conjugated delivery technology, and Phase III outcomes trial-stage development programs.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Lp(a)-Lowering siRNA Market

  • Olpasiran and lepodisiran sustaining the leading share of clinical development activity: These two lead candidates, both enrolled in pivotal cardiovascular outcomes trials, continue to anchor the substantial majority of current siRNA-based Lp(a) market activity.
  • GalNAc-conjugated siRNA architecture sustaining the dominant delivery technology across the category: All three lead clinical programs continue to rely on this targeted hepatic delivery approach for Lp(a) biosynthesis suppression.
  • Ultra-long-duration dosing sustaining structured demand above conventional cardiovascular therapy dosing intervals: Lepodisiran’s demonstrated durability beyond 12 months following a single dose continues to represent an exceptional differentiator within the broader cardiovascular therapeutics landscape.
  • Secondary cardiovascular prevention sustaining the primary current indication while primary prevention expands: Established ASCVD patients with elevated Lp(a) continue to anchor current trial enrollment as primary prevention development activity expands in parallel.
  • Zerlasiran sustaining a differentiated commercial pathway pending partnering activity: Completed Phase II development combined with contingent Phase III advancement continues to distinguish this candidate’s development trajectory from olpasiran and lepodisiran.
  • Phase III clinical-stage development sustaining the entirety of current market activity ahead of first approvals: The complete absence of currently commercialized Lp(a)-lowering siRNA therapy continues to concentrate all market activity within late-stage clinical development.

Market Segmentation: Lp(a)-Lowering siRNA Market

By Product Type
  • Olpasiran (AMG 890)
  • Lepodisiran (LY3819469)
  • Zerlasiran (SLN360)
  • Others
By siRNA Architecture
  • GalNAc-Conjugated siRNA
  • Liver-Targeted siRNA
  • Chemically Modified siRNA
  • Extended-Duration siRNA
  • Next-Generation siRNA
By Indication
  • Atherosclerotic Cardiovascular Disease (ASCVD)
    • Coronary Artery Disease
    • Coronary Heart Disease
    • Myocardial Infarction
    • Ischemic Stroke
    • Peripheral Artery Disease
  • Calcific Aortic Valve Stenosis
  • Elevated Lp(a)-Associated Cardiovascular Risk
  • Primary Cardiovascular Prevention
  • Secondary Cardiovascular Prevention
By Target
  • LPA mRNA
  • Apo(a) mRNA
  • Hepatic LPA Transcript
  • Others
By Mechanism
  • LPA mRNA Silencing
  • RNA-Induced Silencing Complex (RISC)-Mediated mRNA Degradation
  • Apo(a) Production Suppression
  • Hepatic Lp(a) Biosynthesis Inhibition
  • Sustained LPA Expression Suppression
By Delivery
  • GalNAc Conjugation
  • Hepatocyte-Targeted Delivery
  • Others
By Route of Administration
  • Subcutaneous
  • Intravenous
  • Other Parenteral Routes
By Lp(a) Concentration
  • <50 nmol/L
  • 50–125 nmol/L
  • 125–175 nmol/L
  • 175–250 nmol/L
  • 250–400 nmol/L
  • >400 nmol/L
By Dosing Frequency
  • Monthly
  • Every 3 Months
  • Every 4–6 Months
  • Every 6–12 Months
  • Annual / Extended-Duration
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By Treatment Setting
  • Cardiology Centers
  • Preventive Cardiology
  • Lipid Clinics
  • Hospitals & Clinics
  • Specialty Cardiovascular Centers
  • Primary Care
  • Outpatient Specialty Care
By End User
  • Hospitals
  • Cardiology Centers
  • Lipid / Dyslipidemia Clinics
  • Preventive Cardiology Centers
  • Specialty Clinics
  • Primary Care Providers
  • Specialty Pharmacies
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Lp(a)-Lowering siRNA Market

  1. Sustained pivotal outcomes trial enrollment driving lead-candidate clinical development activity: OCEAN(a)-Outcomes and ACCLAIM-Lp(a) continue to anchor the majority of current siRNA-based Lp(a) development attention.
  2. Growing clinical validation of siRNA potency supporting continued modality-driven developer investment: Network meta-analysis findings favoring siRNA reduction magnitudes continue to direct structured research investment toward this modality.
  3. Continued technology investment in ultra-long-duration dosing supporting adherence differentiation: Single-dose durability exceeding 12 months continues to attract structured developer investment pursuing maximally infrequent administration schedules.
  4. Sustained interest in primary cardiovascular prevention broadening the addressable patient population: Extension of siRNA-based Lp(a) reduction beyond secondary prevention continues to generate incremental developer interest in broader indication coverage.
  5. Growing partnering activity supporting continued zerlasiran development: Completed Phase II data continues to attract structured commercialization partner interest pending Phase III outcomes trial initiation.
  6. Maturing Phase III programs supporting an approaching wave of regulatory submissions: Multiple outcomes trials progressing toward completion continue to focus cardiology treatment center and payer attention on the category’s imminent first approvals.

Regional Outlook: Lp(a)-Lowering siRNA Market

  • North America: The United States accounts for the largest share of regional clinical trial activity, supported by extensive cardiology infrastructure and substantial participation in pivotal siRNA-based Lp(a) outcomes trials; regional treatment centers continue to prepare for potential near-term commercial launch.
  • Europe: Germany, the United Kingdom, and the Netherlands anchor regional clinical trial activity, supported by growing specialized lipid clinic capacity and substantial multinational trial participation; this demand base is expected to remain broadly stable through the forecast period.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as regional cardiology centers expand participation in siRNA-based Lp(a) inhibitor clinical development; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized cardiology centers begin to participate in siRNA-based Lp(a) inhibitor clinical trials; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Lp(a)-Lowering siRNA Market

Key Players
Amgen Inc., Eli Lilly and Company, Silence Therapeutics plc, AstraZeneca plc, Arrowhead Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Novartis AG

  • Amgen Inc. [March 2026] — confirmed continued progress for its OCEAN(a)-Outcomes cardiovascular outcomes trial evaluating olpasiran, with the company noting expanding development activity into primary cardiovascular prevention populations.
  • Eli Lilly and Company [December 2025] — reported continued enrollment progress for its ACCLAIM-Lp(a) outcomes trial evaluating lepodisiran, with the company noting sustained investigator interest in its demonstrated single-dose durability profile.
  • Silence Therapeutics plc [September 2025] — confirmed completed Phase II development for zerlasiran, with the company reporting structured interest from potential commercialization partners to support Phase III outcomes trial development.

Consultant POV

The Lp(a)-Lowering siRNA Market’s exceptional 34.0% CAGR outlook through 2035 is anchored in sustained olpasiran and lepodisiran outcomes trial demand, growing ultra-long-duration dosing activity, and continued GalNAc-conjugated hepatocyte targeting adoption. Sustained clinical investment from companies including Amgen Inc., Eli Lilly and Company, and Silence Therapeutics plc confirms the Lp(a)-Lowering siRNA Market will sustain exceptional growth through 2035 as its leading candidates approach potential regulatory decisions.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report